358 related articles for article (PubMed ID: 23322362)
1. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.
Glüer CC; Marin F; Ringe JD; Hawkins F; Möricke R; Papaioannu N; Farahmand P; Minisola S; Martínez G; Nolla JM; Niedhart C; Guañabens N; Nuti R; Martín-Mola E; Thomasius F; Kapetanos G; Peña J; Graeff C; Petto H; Sanz B; Reisinger A; Zysset PK
J Bone Miner Res; 2013 Jun; 28(6):1355-68. PubMed ID: 23322362
[TBL] [Abstract][Full Text] [Related]
2. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis.
Farahmand P; Marin F; Hawkins F; Möricke R; Ringe JD; Glüer CC; Papaioannou N; Minisola S; Martínez G; Nolla JM; Niedhart C; Guañabens N; Nuti R; Martín-Mola E; Thomasius F; Peña J; Graeff C; Kapetanos G; Petto H; Gentzel A; Reisinger A; Zysset PK
Osteoporos Int; 2013 Dec; 24(12):2971-81. PubMed ID: 23740422
[TBL] [Abstract][Full Text] [Related]
3. High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA, reflects vertebral fracture status in men with glucocorticoid-induced osteoporosis.
Graeff C; Marin F; Petto H; Kayser O; Reisinger A; Peña J; Zysset P; Glüer CC
Bone; 2013 Feb; 52(2):568-77. PubMed ID: 23149277
[TBL] [Abstract][Full Text] [Related]
4. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with risedronate and teriparatide in male osteoporosis.
Walker MD; Cusano NE; Sliney J; Romano M; Zhang C; McMahon DJ; Bilezikian JP
Endocrine; 2013 Aug; 44(1):237-46. PubMed ID: 23099796
[TBL] [Abstract][Full Text] [Related]
6. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
7. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
[TBL] [Abstract][Full Text] [Related]
8. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
Hagino H; Kishimoto H; Ohishi H; Horii S; Nakamura T
Bone; 2014 Feb; 59():44-52. PubMed ID: 24184313
[TBL] [Abstract][Full Text] [Related]
10. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
[TBL] [Abstract][Full Text] [Related]
11. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
Mok CC; Tong KH; To CH; Siu YP; Ma KM
Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
[TBL] [Abstract][Full Text] [Related]
12. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
13. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
[TBL] [Abstract][Full Text] [Related]
14. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.
Geusens P; Marin F; Kendler DL; Russo LA; Zerbini CA; Minisola S; Body JJ; Lespessailles E; Greenspan SL; Bagur A; Stepan JJ; Lakatos P; Casado E; Moericke R; López-Romero P; Fahrleitner-Pammer A
J Bone Miner Res; 2018 May; 33(5):783-794. PubMed ID: 29329484
[TBL] [Abstract][Full Text] [Related]
15. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.
Keaveny TM; Donley DW; Hoffmann PF; Mitlak BH; Glass EV; San Martin JA
J Bone Miner Res; 2007 Jan; 22(1):149-57. PubMed ID: 17042738
[TBL] [Abstract][Full Text] [Related]
16. Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis.
Graeff C; Campbell GM; Peña J; Borggrefe J; Padhi D; Kaufman A; Chang S; Libanati C; Glüer CC
Bone; 2015 Dec; 81():364-369. PubMed ID: 26232375
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
18. Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.
Kriel MH; Tobias JH; Creed TJ; Lockett M; Linehan J; Bell A; Przemioslo R; Smithson JE; Brooklyn TN; Fraser WD; Probert CS
Osteoporos Int; 2010 Mar; 21(3):507-13. PubMed ID: 19484170
[TBL] [Abstract][Full Text] [Related]
19. Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
Takakuwa M; Iwamoto J; Itabashi K
Clin Drug Investig; 2012 Feb; 32(2):121-9. PubMed ID: 22185631
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 Jun; 27(6):1989-98. PubMed ID: 26782683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
